Analyst Price Target is $41.27
▲ +73.41% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $41.27, with a high forecast of $52.00 and a low forecast of $28.00. The average price target represents a 73.41% upside from the last price of $23.80.
Current Consensus is
The current consensus among 11 contributing investment analysts is to buy stock in Insmed. This Buy consensus rating has held steady for over two years.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.